Astrazeneca Ab

Craig Samuel Donald

Robert Hugh Bradbury

Alfred Arthur Rabow

David Buttar

Heather Marie Redfearn

Christopher De Savi

Gordon Stuart Currie

Nadim Akhtar

Helen Elizabeth Williams

Matthew Osborne

Neda Yavari

Richard Albert Norman

David R Brittain

Kevin Michael Foote

Roger John Butlin

Michael Howard Block

Thorsten Nowak

Alleyn Thomas Plowright

William McCoull

Alan Martin Birch

Suzanne Saxon Bowker

The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein Rto Rhave any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Chemical compounds

The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein Rto Rhave any of the meanings defined hereinbefore in the description: processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example Ris optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; Ris an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described. 

Oxadiazole derivative as DGAT inhibitors

Compounds of formula (I):wherein: Processes for their preparation and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being are also described.

Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor

Growing community of inventors

Macclesfield, United Kingdom

Craig Samuel Donald